Allergy, Peanut
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
150%
Monoclonal Antibody
150%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
SandozAustria - Kundl
2 programs1
1
ligelizumabPhase 3Monoclonal Antibody1 trial
remibrutinibPhase 2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
DBV TechnologiesDBV712
Sandozligelizumab
Sandozremibrutinib
Clinical Trials (3)
Total enrollment: 887 patients across 3 trials
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Start: Feb 2023Est. completion: Oct 2029600 patients
Phase 3Active Not Recruiting
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
Start: Dec 2021Est. completion: Nov 2023211 patients
Phase 3Terminated
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
Start: Oct 2022Est. completion: Mar 202576 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (50% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.